[Stock Analysis] What is the US Growth Stock DexCom? The Appeal of a Medical Tech Stock Changing the Diabetes Market
For those investing in US stocks, an eternal theme is surely "thematic stocks with expected future growth." Among them, a company currently gathering attention is DexCom.
While our lifestyles have become more affluent, the number of diabetes patients continues to rise globally. According to the International Diabetes Federation (IDF), it is estimated that approximately 589 million adults (aged 20-79) worldwide are living with diabetes. The global number of diabetes patients is projected to reach approximately 650 million by 2030 and approximately 700 million by 2045. DexCom is providing solutions to this massive challenge using the latest technology.
The Continuous Glucose Monitoring (CGM) system developed by DexCom is an innovative product that allows patients to check their blood glucose levels in real-time, significantly improving their daily lives and the quality of their treatment. This field, which fuses medicine and technology, is expected to see continued demand growth and is also attracting attention from investors as a "long-term growth sector."
In other words, DexCom is a company receiving two powerful tailwinds: solving social issues and the expansion of a growth market. It can be said that it is an ideal candidate for starting "long-term investment" in US stocks.
We will introduce DexCom in detail.
1. What kind of company is DexCom?
Basic Information and History
Official Name/Year Established: DexCom, Inc. was founded in 1999 and is a medical device manufacturer headquartered in San Diego, California.
Business Description: Primarily engaged in the design, development, manufacturing, and sale of continuous glucose monitoring systems. It aims to enable diabetes patients to track their blood glucose levels in real-time, improving treatment and lifestyle management.
Philosophy: With a philosophy of "empowering people to take control of their health," the company evolves its technology while reflecting the needs of users, caregivers, and healthcare systems.
Main Products and Technology
CGM Systems (G6, G7, etc.)
G6 and G7 are the current flagship models. They monitor blood glucose levels constantly, and compared to previous versions, they offer longer sensor wear times and improved usability. The G7, in particular, features an integrated sensor and transmitter, making it smaller and more convenient.Stelo
Developed as an over-the-counter (OTC) CGM device that can be used without a prescription. It is a product designed to be more accessible to a wider range of people, including those with type 2 diabetes or pre-diabetes.Software and Services
Through apps and data analysis tools like Dexcom Share and Clarity, the system includes features that allow users to track their blood glucose trends and share them with doctors and caregivers.
Financial and Performance Overview
Sales Growth: In the second quarter of 2025, the company recorded approximately 15% growth compared to the same period last year, with sales of approximately $1.157 billion.
Profit Margins: For the full fiscal year 2025 guidance, non-GAAP gross margin is expected to be approximately 62%, operating margin approximately 21%, and adjusted EBITDA margin approximately 30%.
International Expansion: The company is expanding sales outside the US and increasing the sales share of its international division.
Points of Differentiation
Improvements in accuracy and user convenience are ongoing, and the sensor wear duration and ease of operation are often rated higher than those of competing products.
With the launch of the over-the-counter device (Stelo), the company is successfully tapping into new user segments, including patients with type 2 diabetes and those using it for preventative purposes.
By leveraging software and data analytics (Clarity, Share, etc.), the business model has shifted from simple device sales to a service-oriented approach that promotes monitoring and behavioral change. This is the factor driving recurring revenue.
2. Performance Highlights
Stable annual revenue growth: Market expansion and new product launches are reflected in the figures.
International expansion is a growth driver: Overseas sales are increasing, showing room for growth outside the US.
High profit margins: Profitability is strong as the company grows while keeping costs down.
Bullish outlook: Future performance forecasts are clearly stated, providing reassurance to investors.
2-1. Revenue
Full-year 2024 revenue was approximately $4.033 billion. This is a growth of approximately 11-12% from the previous year.
DexCom has consistently maintained double-digit growth over the past few years. Revenue was approximately $2.9 billion in 2022, increased by 24% year-over-year to approximately $3.6 billion in 2023, and surpassed $4 billion in 2024.
In the most recent second quarter of 2025, revenue was approximately $1.16 billion, a 15% increase year-over-year, and it has already reached the $4.3 billion scale on a trailing twelve-month basis. The expansion of international operations, in particular, is boosting growth, and the realization of sustainable revenue expansion alongside new product launches is a major source of reassurance for investors.
2-2. Net Income
GAAP net income for the second quarter of 2025 was $179.8 million. Net income for the same period last year (second quarter of 2024) was $143.5 million.
On a non-GAAP basis, net income for this quarter was $192.8 million, an increase from the same period last year.
Looking at the annual figures, full-year 2023 net income was approximately $542 million. Net income in 2022 was approximately $341 million, showing a significant improvement year-over-year.
Profit margins are also showing an improving trend, with a net profit margin of approximately 13.3% recorded for the most recent quarter. This indicates that cost management is becoming effective to a certain degree alongside revenue growth.
3. Growth Drivers
3-1. Increasing number of diabetes patients worldwide
The number of people with diabetes worldwide continues to increase year by year. According to a survey by the International Diabetes Federation (IDF), the number of adult patients aged 20-79 reached approximately 589 million as of 2025, and it is projected to exceed 853 million by 2050. It is expected to expand to around 643 million by 2030, and there is no sign that this upward trend will stop.
There are several major factors behind the increase in the number of patients.
Main factors for the increase
Aging population: An increase in the elderly population at high risk for diabetes due to longer life expectancy
Obesity and changes in diet: Expansion of type 2 diabetes due to high-calorie diets and lack of exercise
Urbanization and lifestyle changes: The influence of sedentary lifestyles and the spread of processed foods
Many undiagnosed patients: An estimated 43% (over 250 million people) are unaware they have diabetes
Limited access to medical care: Rapid increase in patients in low- and middle-income countries where diagnosis and treatment are difficult to access
Also, looking at it by region, over 80% of diabetes patients are concentrated in low- and middle-income countries, and the expansion in regions where medical infrastructure is insufficient is particularly serious.
The increase in the number of diabetes patients is a major tailwind for DexCom.
If the absolute number of patients increases, the Continuous Glucose Monitoring (CGM) market will expand
With many undiagnosed individuals and pre-diabetics, there is significant room for acquiring new users
Due to the expansion of lifestyle-related diseases, it is possible to enter not only the treatment market but also the prevention and health management markets
In other words, the social issue of the increase in diabetes patients directly translates into growth potential for DexCom.
3-2. Expansion of the CGM market and technological innovation
Among medical technologies, one of the fields currently receiving the most attention is Continuous Glucose Monitoring (CGM). The global CGM market has grown to a scale of approximately 11 to 14 billion dollars as of 2024, and it is expected to continue expanding at a double-digit annual rate (around 16%). It is projected to reach an even larger market size by the mid-2030s, making it a theme that investors can look forward to in the long term.
This growth is mainly supported by "expansion of insurance coverage" and "evolution of devices".
Expansion of insurance coverage
In 2023, US public health insurance expanded its coverage to include all insulin users as well as non-users at risk of hypoglycemia, leading to widespread adoption, particularly among the elderly.Evolution of devices
Companies are competing on being 'smaller, longer-lasting, and more accurate.' The DexCom G7 has extended its wear time to approximately 15.5 days with improved accuracy, while the Abbott Libre 3 offers 14-day wear without the need for calibration and features strong smartphone management capabilities.Developing new markets (Stelo)
In 2024, DexCom received FDA approval for 'Stelo,' a CGM that does not require a prescription. It can now be used by diabetes patients who do not use insulin as well as for general health management, significantly broadening the market base.Competitors highlight the 'scale of the untapped market'
Abbott notes that 'out of over 500 million diabetes patients, only about 10 million are CGM users,' suggesting the vast potential for adoption. The room for market penetration remains enormous.
3-3. Growth potential through international expansion
While DexCom relies on the US for about two-thirds of its revenue, there is significant room for growth in Europe and Asia. China (approx. 140 million people) and India (approx. 77 million people) are particularly massive potential markets.
According to estimates by the International Diabetes Federation (IDF), more than half of the world's diabetes patients are concentrated in Asia. China has one of the world's largest diabetic populations, India has one of the fastest growth rates, and the number of patients in Southeast Asia is also surging due to urbanization and lifestyle changes.
The Asian market has even greater room for expansion than the US, and the key to adoption is the insurance system. In Europe, public health insurance coverage is expanding, creating an environment where patients can adopt these devices without financial burden.
Although many countries in Asia still lack established systems, it is expected that governments and private insurers will expand their coverage in the future against the backdrop of rising social costs caused by diabetes. If insurance coverage progresses, adoption could accelerate rapidly.
In response to this situation, DexCom is:
Strengthening sales channels and expanding partnerships in Europe and Asia
Obtaining approvals in compliance with national regulations and deploying multilingual apps
Offering high-performance models (G7) in developed countries and low-cost OTC models (Stelo) in emerging markets
and is pursuing such strategies.
What is important for investors is that even if growth in the US stabilizes, Europe and Asia will become new growth engines. Asia, in particular, has a large number of patients but a low penetration rate, so sales growth can be expected as insurance systems are developed. International expansion can be said to be a major key to supporting stock price growth over the next 10 years.
3-4. Expansion into the digital health and wellness market
DexCom is taking a step beyond being a 'medical device manufacturer' and is setting its sights on prevention, self-management, and wellness. Symbols of this include over-the-counter (OTC) CGMs and data services centered on apps. This expands the base beyond the clinical market focused on insulin users to include non-insulin T2D, pre-diabetes, and health-conscious groups.
4. Stock price and investor perspective
DexCom's stock price has grown significantly over the past few years. The background to this includes stable double-digit revenue growth, high profit margins, and the globally expanding diabetes market.
The points that investors should pay attention to are as follows.
Strong Growth Trend
Revenue has expanded steadily over the last three years (from $2.9 billion in 2022 to over $4 billion in 2024), and growth remains strong in Q2 2025 at +15% year-over-year.Potential for International Expansion
While heavily dependent on the US, development in European and Asian markets is underway, with Asia in particular offering significant opportunities due to the combination of a large patient population and low penetration rates.Differentiation Through Technological Innovation
DexCom is expanding its user base with the DexCom G7 and the OTC product 'Stelo,' while diversifying its revenue model through app integration and entry into the wellness market.Risks Investors Should Be Aware Of
1. Price and technology competition with rivals like Abbott
2. Medical regulation and product recall risks
3. High price sensitivity in the wellness market and concerns over declining retention rates
DexCom possesses multiple growth drivers—'Healthcare x Wellness x International Expansion'—that provide the elements to push its stock price higher over the long term. However, given the competition and regulatory risks, it is important to position it as a 'growth stock riding a global market expansion' while remaining mindful of risk management for medium- to long-term investments.
5. Risk Factors
While DexCom continues to show stable growth, investors must be aware of the following risks when making investment decisions.
Intensifying Competition
DexCom faces competition from major companies such as Abbott and Medtronic, and the market environment is extremely challenging. If price competition intensifies, it could lead to lower profit margins, and there is also the risk that users may switch to competitors' products if the company falls behind in technological innovation.Regulatory Risks
DexCom's business depends on medical device approvals in various countries, and its growth speed is influenced by the decisions of the FDA and European regulatory authorities. If the approval of new products is delayed, their launch will be pushed back, which could also put the brakes on international expansion. Furthermore, there are strict legal regulations regarding the handling of medical data, such as HIPAA and GDPR, and compliance with these regulations is a risk factor that constrains business operations.Product Risks
Because CGM is a medical device worn directly on the body, any issues with safety or accuracy could lead to recalls. Such quality problems can significantly damage brand trust and pose a direct risk of poor sales and a decline in stock price.Market Characteristic Risks
Because many users in the wellness market are price-sensitive, there is a concern that long-term continuous use will be difficult and that more people will drop out. Additionally, in emerging markets, medical insurance systems are not yet fully established, so there is a possibility that product adoption may not proceed as expected.
While DexCom has strong growth potential, it is exposed to multiple risks, including competition, regulation, quality, and market characteristics. Although long-term growth expectations are high, it is important for investors to understand that 'high-growth stock' also means 'high volatility'.
Summary
DexCom is a company that provides solutions to the global social issue of diabetes through innovative blood glucose monitoring technology. Revenue has continued to show stable double-digit growth over the past few years, and profit margins remain at a high level. With the introduction of new products and international expansion, sustainable growth is expected to continue.
Furthermore, as symbolized by the over-the-counter 'Stelo,' the company is expanding its reach beyond the medical field into the wellness and preventive medicine markets, which serves as a new growth driver for investors. Although dependence on the US remains high, the potential markets in Europe and Asia are large, and Asia in particular is an untapped blue ocean characterized by a 'large number of patients x low penetration rate'.
On the other hand, risk factors such as price and technology competition with rivals, responses to regulations and product safety, and market characteristics like insurance systems and price sensitivity cannot be ignored. However, even taking these into account, DexCom possesses multiple growth engines—'Healthcare x Wellness x International Expansion'—and has the potential to push its stock price higher over the long term.
For investors, DexCom can be considered a thematic stock suitable for long-term investment, as it is not merely a medical device manufacturer, but a company capable of simultaneously realizing the resolution of global health issues and the expansion of growth markets.
